{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:14:10Z","timestamp":1793020450498,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":367,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"},{"DOI":"10.13039\/100004326","name":"Bayer AG, Wuppertal, Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To describe the baseline characteristics of the participants in the VICTOR (Vericiguat Global Study in Patients with Chronic Heart Failure; NCT05093933) trial and compare them to recent trials in patients with heart failure and reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Baseline characteristics were evaluated in 6105 patients randomized to vericiguat or placebo. The mean age of the participants was 67\u2009\u00b1\u200911\u2009years, 23.6% were women, 64.4% were White, and 10.7% were self-identified Black. Overall, 29.1% of participants were enrolled in Latin and South America, 27.8% and 18.5% in Eastern and Western Europe, 14.0% in Asia-Pacific and 10.6% in North America. The mean left ventricular ejection fraction was 30\u2009\u00b1\u20097% and 79% had New York Heart Association class II symptoms. Mean estimated glomerular filtration rate was 70.9\u2009\u00b1\u200924.0\u2009ml\/min\/1.73\u2009m2. Median N-terminal pro-B-type natriuretic peptide level was 1476 (970\u20132495) pg\/ml and 47.5% of participants had no prior hospitalization for heart failure. Baseline therapy included 94.4% beta-blockers, 94.3% renin\u2013angiotensin system modulation (including 56.0% on an angiotensin receptor\u2013neprilysin inhibitor), 77.7% mineralocorticoid receptor antagonists, 59.1% sodium\u2013glucose cotransporter 2 inhibitors, and 32.9% implantable cardioverter-defibrillators. Overall characteristics were relatively similar to other recent HFrEF trials but the VICTOR trial enrolled a higher proportion of participants receiving contemporary drug and device therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial. These features will facilitate assessment of the benefit of vericiguat and elucidate the outcomes of patients on up-to-date medical therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3598","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T22:00:06Z","timestamp":1739743206000},"page":"1426-1435","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Baseline Characteristics of Contemporary Trial Participants with Heart Failure and Reduced Ejection Fraction: The VICTOR Trial"],"prefix":"10.1093","volume":"27","author":[{"given":"Clara I.","family":"Saldarriaga","sequence":"first","affiliation":[{"name":"Cardio VID Clinic , Medellin ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"CVCT and Universit\u00e9 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran J.","family":"McMullan","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwen","family":"Xing","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Gates","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Anstrom","sequence":"additional","affiliation":[{"name":"University of North Carolina , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[{"name":"Colorado Prevention Center Clinical Research, Department of Medicine, University of Colorado , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Corda","sequence":"additional","affiliation":[{"name":"Bayer AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Ezekowitz","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta , Edmonton, AB ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore and Duke-National University , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldrin F.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Inova Heart and Vascular Institute , Falls Church, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh N.V.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe M.C.","family":"Rosano","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open University of Rome , Rome ,","place":["Italy"]},{"name":"Cardiology, San Raffaele Cassino Hospital , Cassino ,","place":["Italy"]},{"name":"IRCCS San Raffaele Roma , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca , Milan ,","place":["Italy"]},{"name":"Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Udelson","sequence":"additional","affiliation":[{"name":"Tufts Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi , Jackson, MS ,","place":["USA"]},{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,16]]},"reference":[{"key":"2026021721462377000_ejhf3598-bib-0001","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/heartjnl-2021-320131","article-title":"Prevalence, incidence and survival of heart failure: a systematic review","volume":"108","author":"Emmons-Bell","year":"2022","journal-title":"Heart"},{"key":"2026021721462377000_ejhf3598-bib-0002","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026021721462377000_ejhf3598-bib-0003","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"key":"2026021721462377000_ejhf3598-bib-0004","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","article-title":"Health-related quality of life and mortality in heart failure: the Global Congestive Heart Failure study of 23\u2009000 patients from 40 countries","volume":"143","author":"Johansson","year":"2021","journal-title":"Circulation"},{"key":"2026021721462377000_ejhf3598-bib-0005","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026021721462377000_ejhf3598-bib-0006","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2023.05","article-title":"Global public health burden of heart failure: an updated review","volume":"9","author":"Shahim","year":"2023","journal-title":"Card Fail Rev"},{"key":"2026021721462377000_ejhf3598-bib-0007","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004133","article-title":"Heart failure, left ventricular remodeling, and circulating nitric oxide metabolites","volume":"5","author":"Chirinos","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026021721462377000_ejhf3598-bib-0009","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/CIRCRESAHA.118.312708","article-title":"Mitochondrial ROS drive sudden cardiac death and chronic proteome remodeling in heart failure","volume":"123","author":"Dey","year":"2018","journal-title":"Circ Res"},{"key":"2026021721462377000_ejhf3598-bib-0010","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/ejhf.1787","article-title":"Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction","volume":"22","author":"Kramer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721462377000_ejhf3598-bib-0011","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jchf.2022.04.015","article-title":"Sequential evaluation of NT-proBNP in heart failure: insights into clinical outcomes and efficacy of vericiguat","volume":"10","author":"Armstrong","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026021721462377000_ejhf3598-bib-0012","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ejhf.3501","article-title":"Vericiguat global study in participants with chronic heart failure: design of the VICTOR trial","volume":"27","author":"Reddy","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721462377000_ejhf3598-bib-0013","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0014","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0016","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0018","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejhf.1664","article-title":"Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial","volume":"21","author":"Pieske","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021721462377000_ejhf3598-bib-0019","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/ejhf.2015","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials","volume":"22","author":"Teerlink","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721462377000_ejhf3598-bib-0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721462377000_ejhf3598-bib-0021","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021721462377000_ejhf3598-bib-0022","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/ejhf.3005","article-title":"Residual risk in heart failure and the need for simultaneous implementation and innovation","volume":"25","author":"Fatima","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021721462377000_ejhf3598-bib-0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609758","article-title":"Declining risk of sudden death in heart failure","volume":"377","author":"Shen","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0024","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia","volume":"335","author":"Moss","year":"1996","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0025","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1056\/NEJM199912163412503","article-title":"A randomized study of the prevention of sudden death in patients with coronary artery disease","volume":"341","author":"Buxton","year":"1999","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0026","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"2026021721462377000_ejhf3598-bib-0027","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1161\/CIR.0000000000000534","article-title":"Cardiovascular health in African Americans: a scientific statement from the American Heart Association","volume":"136","author":"Carnethon","year":"2017","journal-title":"Circulation"},{"key":"2026021721462377000_ejhf3598-bib-0028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/HCO.0000000000000855","article-title":"Racial and ethnic disparities in heart failure: Current state and future directions","volume":"36","author":"Lewsey","year":"2021","journal-title":"Curr Opin Cardiol"},{"key":"2026021721462377000_ejhf3598-bib-0029","article-title":"Representation of women in heart failure clinical trials: Barriers to enrollment and strategies to close the gap","volume":"13","author":"Reza","year":"2022","journal-title":"Am Heart J Plus"},{"key":"2026021721462377000_ejhf3598-bib-0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jchf.2019.12.010","article-title":"Natriuretic peptides as inclusion criteria in clinical trials: A JACC: Heart failure position paper","volume":"8","author":"Ibrahim","year":"2020","journal-title":"JACC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/8\/1426\/66813400\/eurjhf_27_8_1426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/8\/1426\/66813400\/eurjhf_27_8_1426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:46:35Z","timestamp":1771382795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/8\/1426\/8468090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,16]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,2,16]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3598","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,2,16]]},"assertion":[{"value":"2024-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}